Loading companies…
RT
Retham Technologies, Inc.
United States · Healthtech
Retham is developing HITDx, a functional hospital-lab assay for heparin-induced thrombocytopenia that uses stable cryopreserved donor platelets to make clinically relevant platelet testing more practical; the diagnostic is in validation and regulatory development, while its cryopreserved platelets are available for research use.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed | $1.5M | Talents Fund — LeadGolden Angels Investors — ParticipantMilwaukee Venture Partners — Participant |
Investors
Talents FundLed SeedGolden Angels InvestorsJoined SeedMilwaukee Venture PartnersJoined SeedCoverage
Sep 15, 2026Retham Technologies, Inc. · SeedSimilar companies
GMGeneral MedicineAn online healthcare store where people compare care options and upfront prices, book visits and order medications or lab tests.$120M · Series B
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
Blue Health IntelligenceBlue Health Intelligence combines a one-hour health assessment with doctor-led interpretation and a digital plan for preventive care.€3.4M · €3.4 million growth capital